Display options
Share it on

Pharmacoecon Open. 2021 Jun;5(2):197-209. doi: 10.1007/s41669-020-00236-5. Epub 2020 Nov 09.

Minimally Invasive Sacroiliac Joint Fusion with Triangular Titanium Implants: Cost-Utility Analysis from NHS Perspective.

PharmacoEconomics - open

Deirdre B Blissett, Rob S Blissett, Matthew P Newton Ede, Philip M Stott, Daniel J Cher, W Carlton Reckling

Affiliations

  1. MedTech Economics Ltd., Winchester, UK. [email protected].
  2. MedTech Economics Ltd., Winchester, UK.
  3. The Royal Orthopaedic Hospital, Bristol Road South, Birmingham, UK.
  4. Precision Spine, 81 Harborne Road, Edgbaston, Birmingham, UK.
  5. Brighton and Sussex University Hospitals NHS Trust, Eastern Road, Brighton, UK.
  6. Department of Clinical Affairs, SI-BONE, Inc., San Jose, CA, USA.
  7. Department of Medical Affairs, SI-BONE, Inc., San Jose, CA, USA.

PMID: 33165824 PMCID: PMC8160075 DOI: 10.1007/s41669-020-00236-5

Abstract

OBJECTIVE: The aim was to identify the cost-effectiveness of minimally invasive sacroiliac joint fusion (MI SIJF) surgery with titanium triangular implants for patients with sacroiliac joint (SIJ) pain who have failed conservative management, compared to non-surgical management (NSM) from a National Health Service (NHS) England perspective.

METHODS: Over a time horizon of 5 years, a cohort state transition model compared the costs and outcomes of treating patients with MI SIJF to those of traditional NSM treatment pathways. The NSM arm included two treatments: grouped physical therapy and corticosteroid injections (PTSI) or radiofrequency ablation (RFA). Three different strategies were considered: (1) a stepped pathway, (2) patients split between PTSI and RFA, and (3) RFA only. The outcome measure was incremental cost-effectiveness ratio (ICER), reported in 2018 British pounds per quality-adjusted life year (QALY) gained. One-way and probabilistic sensitivity analyses were used to test the robustness of the model results.

RESULTS: Patients undergoing MI SIJF accrued total procedure-related and pain-management costs of £8358, while NSM treatment strategy 1 had total costs of £6880. The MI SIJF cohort had 2.98 QALYs compared to strategy 1 with 2.30 QALYs. This resulted in an ICER for MI SIJF versus strategy 1 of £2164/QALY gained. Strategy 2 of the NSM arm had lower costs than strategy 1 (£6564) and 2.26 QALYs, and this resulted in an ICER of £2468/QALY gained for MI SIJF. Strategy 3 of the NSM arm had lower costs than strategy 1 (£6580), and this resulted in 2.28 QALYs and an ICER of £2518/QALY gained for MI SIJF. Probabilistic sensitivity analysis shows that at a threshold of £20,000/QALY gained, MI SIJF has a probability of being cost-effective versus NSM strategies of 96%, 97%, and 91% for strategies 1, 2, and 3, respectively.

CONCLUSION: MI SIJF appears to be cost-effective over a 5-year time horizon when compared to traditional NSM pathways in an NHS context.

References

  1. Ann Rheum Dis. 2012 Nov;71(11):1796-802 - PubMed
  2. Neurosurgery. 2018 Jan 1;82(1):48-55 - PubMed
  3. Qual Life Res. 2016 Feb;25(2):283-292 - PubMed
  4. Appl Health Econ Health Policy. 2020 Jun;18(3):363-373 - PubMed
  5. Pain Physician. 2015 Sep-Oct;18(5):E713-56 - PubMed
  6. Clinicoecon Outcomes Res. 2015 Dec 18;8:1-14 - PubMed
  7. Spine (Phila Pa 1976). 2013 Jan 15;38(2):157-68 - PubMed
  8. Pain. 2000 Jan;84(1):95-103 - PubMed
  9. JAMA. 2017 Jul 4;318(1):68-81 - PubMed
  10. Pain Med. 2015 Aug;16(8):1500-18 - PubMed
  11. Spine (Phila Pa 1976). 2017 Nov 1;42(21):1664-1673 - PubMed
  12. Pain Med. 2011 May;12(5):732-9 - PubMed
  13. J Altern Complement Med. 2010 Dec;16(12):1285-90 - PubMed
  14. Int J Spine Surg. 2015 Mar 05;9:6 - PubMed
  15. Eur Spine J. 2017 Mar;26(3):708-719 - PubMed
  16. BMJ Qual Improv Rep. 2017 Feb 10;6(1): - PubMed
  17. Pain Med. 2012 Mar;13(3):383-98 - PubMed
  18. Spine J. 2005 Sep-Oct;5(5):520-8; discussion 529 - PubMed
  19. Pain Med. 2009 Jul-Aug;10(5):850-3 - PubMed
  20. Clin J Pain. 2016 Nov;32(11):921-926 - PubMed
  21. Lancet. 2012 Dec 15;380(9859):2197-223 - PubMed
  22. Pain Physician. 2018 Sep;21(5):489-496 - PubMed
  23. Clin Orthop Relat Res. 2014 Jun;472(6):1831-8 - PubMed
  24. Med Devices (Auckl). 2018 Sep 28;11:337-343 - PubMed
  25. PM R. 2019 Aug;11 Suppl 1:S98-S104 - PubMed
  26. Pharmacoeconomics. 2007;25(1):3-6 - PubMed
  27. Medicine (Baltimore). 2018 Feb;97(6):e9809 - PubMed
  28. Int J Spine Surg. 2016 Aug 23;10:28 - PubMed
  29. Med Devices (Auckl). 2015 Nov 23;8:485-92 - PubMed
  30. Ann Surg Innov Res. 2013 Oct 30;7(1):14 - PubMed
  31. PM R. 2019 Aug;11 Suppl 1:S105-S113 - PubMed
  32. Expert Rev Neurother. 2013 Jan;13(1):99-116 - PubMed
  33. Health Technol Assess. 2017 May;21(30):1-184 - PubMed
  34. Int J Spine Surg. 2015 Jul 22;9:40 - PubMed
  35. Pain Med. 2011 Apr;12(4):565-70 - PubMed
  36. Med Devices (Auckl). 2014 Jun 05;7:187-93 - PubMed
  37. Anesthesiology. 2008 Aug;109(2):279-88 - PubMed
  38. Med Devices (Auckl). 2019 Sep 26;12:411-422 - PubMed
  39. Eur Spine J. 2008 Jun;17(6):794-819 - PubMed
  40. BMJ. 2009 Jun 04;338:b1805 - PubMed

Publication Types